ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, issue.14, pp.3901-3910, 2011. ,
DOI : 10.1182/blood-2010-11-317438
Molecular pathogenesis of multiple myeloma: basic and clinical updates, International Journal of Hematology, vol.97, issue.3, pp.313-323, 2013. ,
DOI : 10.1007/s12185-013-1291-2
Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation, Journal of Biological Chemistry, vol.287, issue.13, pp.10224-10235, 2012. ,
DOI : 10.1074/jbc.M111.334532
Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines, Cell Death and Disease, vol.4, issue.10, p.880, 2013. ,
DOI : 10.1074/jbc.M112.391854
Apoptotic Machinery Diversity in Multiple Myeloma Molecular Subtypes, Frontiers in Immunology, vol.4, p.467, 2013. ,
DOI : 10.3389/fimmu.2013.00467
Emerging Therapeutics Targeting mRNA Translation, Cold Spring Harbor Perspectives in Biology, vol.4, issue.4, 2012. ,
DOI : 10.1101/cshperspect.a012377
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312682
Proteasomal Degradation of Mcl-1 by Maritoclax Induces Apoptosis and Enhances the Efficacy of ABT-737 in Melanoma Cells, PLoS ONE, vol.5, issue.11, p.78570, 2013. ,
DOI : 10.1371/journal.pone.0078570.s001
Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells, Cancer Research, vol.72, issue.17, pp.4562-4573, 2012. ,
DOI : 10.1158/0008-5472.CAN-12-0487
Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner, Oncotarget, vol.6, issue.14, pp.12668-12681, 2015. ,
DOI : 10.18632/oncotarget.3706
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins, Genes & Development, vol.19, issue.11, pp.1294-1305, 2005. ,
DOI : 10.1101/gad.1304105
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1142553